T
Tessa Therapeutics
Clinical-stage biotechnology company focused on the development
About Tessa Therapeutics
Tessa Therapeutics is a biopharmaceutical company that specializes in the development and commercialization of cell therapies for cancer treatment. The company operates in the healthcare sector, specifically in the field of oncology. It serves a broad range of clients, including hospitals, healthcare providers, and patients suffering from various types of cancer.
Tessa Therapeutics' business model revolves around the research, development, and commercialization of innovative cell therapies. The company's primary source of revenue comes from the sale of these therapies to healthcare providers. It also generates income from partnerships with other pharmaceutical and biotech companies, where it licenses its technology or collaborates on joint research projects.
The company's flagship product is a type of cell therapy known as Virus-Specific T cells (VSTs). These are a new class of drugs that use the body's own immune system to fight cancer. The therapy involves extracting T cells (a type of white blood cell) from a patient, modifying them in a lab to target specific viruses associated with cancer, and then reintroducing them into the patient's body. This approach has shown promise in treating a variety of cancers, including nasopharyngeal carcinoma (a type of head and neck cancer), and cervical cancer.
In summary, Tessa Therapeutics is a biopharmaceutical company that operates in the oncology market. It generates revenue through the sale of its innovative cell therapies and through partnerships with other companies in the healthcare sector.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | May 2023 | $100K | — | Undisclosed | ↗ |
| SERIES AOther financing | Jun 2022 | $126M | $504M | EDBI · Temasek · Heritas Capital Management · Polaris Partners | ↗ |
Growth signals
Latest recorded traffic for Tessa Therapeutics is 1K monthly website visits, down 16.7% over the last three months. Tessa Therapeutics's team declined 10.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tessa Therapeutics in the Singapore ecosystem
The Tessa Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Polaris Partners
Heritas Capital Management
Series B and later3 investors entered at this stage
EDBI
Temasek
Heliconia Capital Management
Other known investors1 additional known investor
Baylor College of Medicine
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tessa Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tessa Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









